Literature DB >> 3675136

Neuroendocrine responses to intravenous tryptophan in major depression.

P J Cowen1, E M Charig.   

Abstract

The increases in plasma levels of prolactin (PRL) and growth hormone (GH) following intravenous administration of the 5-hydroxytryptamine precursor tryptophan (100 mg/kg) were assessed in 30 depressed patients and 30 control subjects. In depressed patients who lost less than 10 lb, PRL responses were significantly reduced compared with controls. In contrast, the PRL responses of patients with weight loss exceeding 10 lb were significantly greater than those of either controls or the other depressed patients. Growth hormone responses to tryptophan were significantly decreased in patients who lost less than 10 lb. Prolactin, but not GH, responses correlated significantly with the postdexamethasone plasma cortisol concentration; however, an apparent relationship between GH and PRL responses and suicidal behavior was probably due to the common factor of weight loss. The results suggest that depressed patients have different types of abnormal 5-hydroxytryptamine-mediated neuroendocrine responses that correlate with the presence or absence of severe weight loss and cortisol hypersecretion. Further investigations are needed to establish if these abnormalities are central to the depressive disorder or have implications for treatment response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3675136     DOI: 10.1001/archpsyc.1987.01800230038008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  12 in total

Review 1.  The role of serotonin in eating disorders.

Authors:  S F Leibowitz
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Lithium and serotonin function: implications for the serotonin hypothesis of depression.

Authors:  L H Price; D S Charney; P L Delgado; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Affective cognition and its disruption in mood disorders.

Authors:  Rebecca Elliott; Roland Zahn; J F William Deakin; Ian M Anderson
Journal:  Neuropsychopharmacology       Date:  2010-06-23       Impact factor: 7.853

Review 4.  Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap.

Authors:  P Tibbo; L Warneke
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

5.  5-HTTLPR and gender moderate changes in negative affect responses to tryptophan infusion.

Authors:  Beverly H Brummett; Christopher L Muller; Ann L Collins; Stephen H Boyle; Cynthia M Kuhn; Ilene C Siegler; Redford B Williams; Allison Ashley-Koch
Journal:  Behav Genet       Date:  2008-07-26       Impact factor: 2.805

Review 6.  Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter.

Authors:  Alexander Neumeister; Theresa Young; Juergen Stastny
Journal:  Psychopharmacology (Berl)       Date:  2004-07-13       Impact factor: 4.530

7.  A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation.

Authors:  J F Deakin; I Pennell; A J Upadhyaya; R Lofthouse
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

Review 9.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

10.  Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.

Authors:  H Y Meltzer; M Maes
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.